2010年卵巢癌诊疗指引课件_1.ppt

01.NCCN (National Comprehensive Cancer Network) Practice Guidelines in Oncology version 1. 2010 in Ovarian Cancer. 02.NCI (National Cancer Institute) Ovarian Epithelial Cancer Treatment Health Profes- sional Version (date last modified: March 17, 2003). 03.NCI (National Cancer Institute) Ovarian Low Malignant Potential Tumors Treatment Health Professional Version (date last modified: June 19, 2003). 04.FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 2000; 70:209-262. 05.Standards, Options and Recommendations. Clinical practice guidelines for cancer care from the French National Federation of Cancer (FNCLCC). Ovarian cancer. Bri J Cancer 2001; 84(Suppl 2):18-23. 06.Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, 2nd ed, chap 32, pp 939-941. Philadelphia, Lippincott Williams Wilkins, 1997. 07.Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40:103-106. 08.Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experi- ence. J Clin Oncol 1991; 9:1138-1150. 09.Van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7:769-773. 10.Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27:1367-1372. 11.Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreduct